J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”
Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...
Company
Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy
Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...
Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris
US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...
Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC
Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...
RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC
Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...
Lepu Biopharma’s MRG002 Earns FDA Orphan Drug Status for Gastric Cancer
China’s Lepu Biopharma Co., Ltd (HKG: 2157) announced that the U.S. FDA has granted orphan...
Jacobio Pharmaceuticals Doses First Patient in JAB-21822 Phase IIa Trial for KRAS G12C NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...
Novartis Partners with Beijing’s Changping District to Expand Drug Development
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...
GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales
Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue...
Mayo Clinic Launches Mayflower BioVentures to Accelerate Cell and Gene Therapies
The Mayo Clinic, a leading US hospital group, has launched Mayflower BioVentures, a cell and...
Biointron Raises USD 72M in Series B to Expand CRO Services and Antibody Platform
Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500...
Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in...
Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization
China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022...
Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC
China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug...
RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales
China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for...
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...
RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China
US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company,...
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...
E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised...